Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Общий артериальный ствол

Список литературы

  1. Андреева Н. С., Реброва О. Ю., Зорин Н. А., др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор 2012; 4: 10–24.
  2. Джонс Кеннет Л. Наследственные синдромы по Дэвиду Смиту. Атлас-справочник. Москва. Практика. 2011.
  3. Белоконь Н.А., Подзолков В.П. Врожденные пороки сердца. Москва. Медицина. 1991.
  4. Бокерия Л.А., Шаталов К.В. Детская кардиохирургия. Руководство для врачей. Москва. НЦССХ им. А.Н. Бакулева. 2016.
  5. Iffy L., Shepard T.H., Jakobovits A., Lemire R.J., Kerner P. The rate of growth in young human embryos of Streeter"s horizons. 13 to 23. Acta Anat (Basel). 1967;66(2):178-86.
  6. Goldmuntz E., Driscoll D., Budarf M.L., et al. Microdeletions of chromosomal region 22q11 in patients with congenital conotruncal cardiac defects. J Med Genet. 1993;30(10):807-812. doi:10.1136/jmg.30.10.807
  7. Kouchoukos N.T., Blackstone E.H., Hanley F.L., Kirklin J.K. Kirklin/Barratt-Boyes cardiac surgery: morphology, diagnostic criteria, natural history, techniques, results, and indications. – 4th ed. Philadelphia: Elsevier; 2013.
  8. Francalanci P., Gallo P., Dallapiccola B., Calabrese G., Marino B. A genetic assessment of trisomy 21 in a patient with persistent truncus arteriosus who died 38 years ago. Am J Cardiol. 1997 Jan 15;79(2):245-7. doi: 10.1016/s0002-9149(97)89293-4.
  9. Moore J.W., Wight N.E., Jones M.C., Krous H.F. Truncus arteriosus associated with trisomy 18. Pediatr Cardiol. 1994 May-Jun;15(3):154-6. doi: 10.1007/BF00796330.
  10. Yasuda K., Morihana E., Fusazaki N., Ishikawa S. Cardiovascular Malformations in CHARGE Syndrome with DiGeorge Phenotype: Two Case Reports. Case Rep Pediatr. 2016;2016:8013530. doi: 10.1155/2016/8013530.
  11. Ferencz C., Rubin J.D., McCarter R.J., Clark E.B. Maternal diabetes and cardiovascular malformations: predominance of double outlet right ventricle and truncus arteriosus. Teratology. 1990 Mar;41(3):319-26. doi: 10.1002/tera.1420410309.
  12. Бураковский В.И., Бокерия Л.А. Руководство по сердечно-сосудистой хирургии. Москва. Медицина 1994.
  13. Adachi I., Seale A., Uemura H., McCarthy K.P., Kimberley P., Ho S.Y. Morphologic spectrum of truncal valvar origin relative to the ventricular septum: correlation with the size of ventricular septal defect. J Thorac Cardiovasc Surg. 2009 Dec;138(6):1283-9. doi: 10.1016/j.jtcvs.2009.05.009. 
  14. Ly R., Mousseaux E., Iserin L., Ladouceur M. Multimodality imaging before persistent truncus arteriosus repair in a 36-year-old woman. Eur Heart J Case Rep. 2020;4(6):1-2. Published 2020 Nov 9. doi:10.1093/ehjcr/ytaa385
  15. Talwar S., Agarwal P., Choudhary S.K., Kothari S.S., Juneja R., Saxena A., Airan B. Aortopulmonary window: Morphology, diagnosis, and long-term results. J Card Surg. 2017 Feb;32(2):138-144. doi: 10.1111/jocs.12936.
  16. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых (клиническая рекомендация). Грудная и сердечно-сосудистая хирургия. 2017; 59 (2): 135-147. DOI: 10.24022/0236-2791-2017-59-2-135-147
  17. Авдеев С.Н., Горбачевский С.В., Алдашев А.А. Легочная гипертензия. ГЭОТАР-Медиа. 2015.
  18. Горбачевский С.В., Мукимов Ф.Х., Шмальц А.А., Гренадеров М.А., Кольцов М.А., Хальвани М.А.. Эффективность двухэтапной хирургической коррекции дефекта межжелудочковой перегородки, осложненного синдромом Эйзенменгера. Детские болезни сердца и сосудов. 2014; (): -. DOI:
  19. Tuder R.M., Abman S.H., Braun T., et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S3–S9.
  20. Oechslin E., Kiowski W., Schindler R., et al. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005; 112:1106–1112.
  21. Gasul B.M., Arcilla R.A. and Lev M.: Heart Disease in Children, Philadelphia, 1966, 1. B. Lippincott Company, chap. 24, p. 617
  22. Kidd B.S.L.: Persistent truncus arteriosus. In Heart Disease In Infancy and Childhood. 3rd ed, Keith J.D., Rowe R.D., Vlad .P (Eds). Macmillan, New York, 1978.
  23. McNamara D.G., Sommerville R.J.: Truncus arteriosus. In Heart Disease in Infants, Children and Adolescents, edited by Moss AJ, Adams FH. Baltimore, Williams & Wilkins Company, 1968, pp 637-657
  24. Bharati S., Lev M. The Pathology of Congenital Heart Disease. A personal expierence of more than 6.300 Congenitally Malformed Hearts. Volume 1. P. 658.
  25. Van Praagh R., Van Praagh S. The anatomy of common aorticopulmonary trunk (truncus arteriosus communis) and its embryologic implications. A study of 57 necropsy cases. Am J Cardiol. 1965 Sep;16(3):406-25. doi: 10.1016/0002-9149(65)90732-0. 
  26. Volpe P., Paladini D., Marasini M., et al. Common arterial trunk in the fetus: characteristics, associations, and outcome in a multicentre series of 23 cases. Heart. 2003;89(12):1437-1441. doi:10.1136/heart.89.12.1437
  27. Perloff Joseph K. Clinical recognition of Congenital Heart Disease. Fifth Edition. Saunders. 2003.
  28. Engelfriet P.M., Duffels M.G., Möller T., Boersma E., Tijssen J.G., Thaulow E., Gatzoulis M.A., Mulder B.J. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007 Jun;93(6):682-7. doi: 10.1136/hrt.2006.098848. 
  29. Hicken P., Evans D., Heath D. Persistent truncus arteriosus with survival to the age of 38 years. Br Heart J. 1966 Mar;28(2):284-6. doi: 10.1136/hrt.28.2.284. PMID: 4952254; 
  30. Kim H.S., Kim Y.H. Persistent truncus arteriosus with aortic dominance in female adult patient. J Cardiovasc Ultrasound. 2015 Mar;23(1):32-5. doi: 10.4250/jcu.2015.23.1.32. 
  31. Williams-Phillips S. Truncus arteriosus 5th decade transesophageal and transthoracic echocardiogram features. J Cardiol Cases. 2014 May 17;10(1):25-30. doi: 10.1016/j.jccase.2014.04.001. 
  32. Becker A.E., Becker M.J., Edwards J.E. Pathology of the semilunar valve in persistent truncus arteriosus. J Thorac Cardiovasc Surg. 1971 Jul;62(1):16-26.
  33. Collett R.W., Edwards Y.E. Persistent truncus arteriosus. A classification according to anatomic subtypes. Surg Chin North Am 1949;29:1245.
  34. De Leval M. Persistent truncus arteriosus. In: Stark J, de Leval M, eds. Surgery for congenital heart defects, 2nd ed. Philadelphia: WB Saunders Company, 1994:539–49.
  35. Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016. 37:67–119.
  36. Jacobs M.L. Congenital Heart Surgery Nomenclature and Database Project: truncus arteriosus. Ann Thorac Surg. 2000 Apr;69 (4 Suppl):S50-5. doi: 10.1016/s0003-4975(99)01320-x. 
  37. Myung K. Park. Miscellaneous Congenital Cardiac Conditions in Pediatric Cardiology for Practitioners (Fifth Edition), 2008
  38. Spinner J.A., Morris S.A., Nandi D., Costarino A.T., Marino B.S., Rossano J.W., Shamszad P. Necrotizing Enterocolitis and Associated Mortality in Neonates With Congenital Heart Disease: A Multi-Institutional Study. Pediatr Crit Care Med. 2020 Mar;21(3):228-234. doi: 10.1097/PCC.0000000000002133. 
  39. Brown J.W., Ruzmetov M., Okada Y., Vijay P., Turrentine M.W., Truncus arteriosus repair: outcomes, risk factors, reoperation and management, European Journal of Cardio-Thoracic Surgery, Volume 20, Issue 2, August 2001, Pages 221–227, https://doi.org/10.1016/S1010-7940(01)00816-8
  40. Tlaskal T., Chaloupecky V., Hucin B, Gebauer R, Krupickova R, Reich O, Skovranek J, Tax P. Long-term results after correction of persistent truncus arteriosus in 83 patients, , European Journal of Cardio-Thoracic Surgery, Volume 37, Issue 6, June 2010, Pages 1278–1284, https://doi.org/10.1016/j.ejcts.2009.12.022
  41. Alamri R., Dohain A., Arafat A.A. et al. Surgical repair for persistent truncus arteriosus in neonates and older children. J Cardiothorac Surg 15, 83 (2020). https://doi.org/10.1186/s13019-020-01114-1
  42. Asagai S., Inai K., Shinohara T., Tomimatsu H., Ishii T., Sugiyama H., Park I.-S., Nagashima, M. and Nakanishi, T. (2016), Long-term Outcomes after Truncus Arteriosus Repair: A Single-center Experience for More than 40 Years. Congenital Heart Disease, 11: 672-677. https://doi.org/10.1111/chd.12359
  43. Rajasinghe H.A., McElhinney D.B., Reddy V.M., Mora B.N., Hanley F.N. Long-term follow-up of truncus arteriosus repaired in infancy: A twenty-year experience, The Journal of Thoracic and Cardiovascular Surgery, Volume 113, Issue 5, 1997, Pages 869-879, https://doi.org/10.1016/S0022-5223(97)70259-9.
  44. Schreiber C., Eicken A., Balling G., Wottke M., Schumacher G., Un Paek S., Meisner H., Hess J., Lange R. Single centre experience on primary correction of common arterial trunk: overall survival and freedom from reoperation after more than 15 years. Eur J Cardiothorac Surg. 2000 Jul;18(1):68-73. doi: 10.1016/s1010-7940(00)00449-8. 
  45. Castaneda A.R., Jonas R.A., Mayer JE Jr, Hanley F.L. Cardiac Surgery of the Neonate and Infant. Philadelphia, PA: W.B. Saunders Company; 1994.
  46. Phadke M.S., Sabnis G.R., Patil D.V., Lanjewar C.P., Kerkar P.G. An extremely rare cause of Eisenmenger syndrome. Indian Heart J. 2014;66(6):737-739. doi:10.1016/j.ihj.2014.10.397
  47. Hansmann G. Pulmonary Hypertension in Infants, Children, and Young Adults. J Am Coll Cardiol. 2017 May 23;69(20):2551-2569. doi: 10.1016/j.jacc.2017.03.575.
  48. Клинические рекомендации: Легочная гипертензия. http://cr.rosminzdrav.ru/#!/schema/136 (дата обращения 22.03.2020г.).
  49. Stout K.K., Daniels C.J., Aboulhosn J.A. et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e637-e697. doi: 10.1161/CIR.0000000000000602.
  50. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br Med J. 1958;2(5098):701-709. doi:10.1136/bmj.2.5098.701
  51. Freedom R.M., Rosen F.S., Nadas A.S. Congenital cardiovascular disease and anomalies of the third and fourth pharyngeal pouch. Circulation. 1972 Jul;46(1):165-72. doi: 10.1161/01.cir.46.1.165. 
  52. Niwa K., Perloff J.K., Kaplan S., Child J.S., Miner P.D. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol. 1999 Jul;34(1):223-32. doi: 10.1016/s0735-1097(99)00153-9. 
  53. Farrell M.J., Stadt H., Wallis K.T., Scambler P., Hixon R.L., Wolfe R., Leatherbury L., Kirby M.L. HIRA, a DiGeorge syndrome candidate gene, is required for cardiac outflow tract septation. Circ Res. 1999 Feb 5;84(2):127-35. doi: 10.1161/01.res.84.2.127.
  54. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009. 30:2493-2537.
  55. Румянцев А.Г., Масчан А.А. Федеральные клинические рекомендации по диагностике и лечению синдрома делеции 22-й хромосомы. Национальное общество детских гематологов, онкологов России. 2014.
  56. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2020; 1: 78-122.
  57. Marilyn J. Bull, the Committee on Genetics. Health Supervision for Children With Down Syndrome. Pediatrics Aug 2011, 128 (2) 393-406; DOI: 10.1542/peds.2011-1605
  58. Cereda A., Carey J.C. The trisomy 18 syndrome. Orphanet J Rare Dis. 2012;7:81. Published 2012 Oct 23. doi:10.1186/1750-1172-7-81
  59. Perloff J.K. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993;11:689–699.
  60. Tandon R., Hauck A.I., Nadas A.S. Persistent truncus arteriosus. A clinical, hemodynamic, and autopsy study of nineteen cases. Circulation. 1963 Dec;28:1050-60. doi: 10.1161/01.cir.28.6.1050.
  61. Чазова И.Е., Мартынюк Т.В., др. Диагностика и лечение легочной гипертензии. Российские рекомендации. Кардиоваскулярная терапия и профилактика 2007; 6: Приложение 2.
  62. Broberg C.S., Ujita M., Prasad S., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50: 634–642.
  63. Bonderman D., Wexberg P., Martischnig A.M., Heinzl H., Lang M.B., Sadushi R., Skoro-Sajer N., Lang I.M. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011;37:1096–1103.
  64. Rich J.D., Thenappan T., Freed B., Patel A.R., Thisted R.A., Childers R., Archer S.L. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
  65. Armstrong W.F. Ryan Th. Feigenbaum"s Echocardiography, 7th Edition. 2010 Lippincott Williams & Wilkins.
  66. Tworetzky W., McElhinney D.B., Brook M.M., Reddy V.M., Hanley F.L., Silverman N.H. Echocardiographic diagnosis alone for the complete repair of major congenital heart defects. J Am Coll Cardiol. 1999 Jan;33(1):228-33. doi: 10.1016/s0735-1097(98)00518-x.
  67. Saxena A., Shrivastava S. Echocardiographic-angiocardiographic correlation in persistent truncus arteriosus. Indian J Pediatr. 1989 Mar-Apr;56(2):273-6. doi: 10.1007/BF02726624.
  68. Duke C., Sharland G.K., Jones A.M., Simpson J.M. Echocardiographic features and outcome of truncus arteriosus diagnosed during fetal life. Am J Cardiol. 2001 Dec 15;88(12):1379-84. doi: 10.1016/s0002-9149(01)02117-8.
  69. Traisrisilp K., Tongprasert F., Srisupundit K., Luewan S., Sukpan K., Tongsong T. Prenatal differentiation between truncus arteriosus (Types II and III) and pulmonary atresia with ventricular septal defect. Ultrasound Obstet Gynecol. 2015 Nov;46(5):564-70. doi: 10.1002/uog.14788. 
  70. Nagaraja P.S., Singh N.G., Simha P.P., Davan K.R., Manjunath V., Jagadeesh A.M. Role of perioperative transesophageal echocardiography in the management of adolescent truncus arteriosus: rare case report. Ann Card Anaesth. 2015;18(2):234-236. doi:10.4103/0971-9784.154487
  71. Mir A., Burkhart H.M., Ponniah K., Ward K. Intramural Coronary Artery in Truncus Arteriosus: Importance of Preoperative Echocardiographic Diagnosis and Impact on Surgical Planning. World J Pediatr Congenit Heart Surg. 2018 May;9(3):368-370. doi: 10.1177/2150135116682453. 
  72. Debl K., Djavidani B., Buchner S., et al. Quantification of left-to-right shunting in adult congenital heart disease: phase-contrast cine MRI compared with invasive oximetry. Br J Radiol. 2009; 82(977):386-91.
  73. Saremi F. Cardiac CT and MR for Adult Congenital Heart Disease. Springer. 2014.
  74. Robinson Vimala L., Hanneman K., Thavendiranathan P., Nguyen E.T., Silversides C.K., Wald R.M. Characteristics of Cardiovascular Magnetic Resonance Imaging and Outcomes in Adults With Repaired Truncus Arteriosus. Am J Cardiol. 2019 Nov 15;124(10):1636-1642. doi: 10.1016/j.amjcard.2019.08.007.
  75. Chikkabyrappa S., Mahadevaiah G., Buddhe S., Alsaied T., Tretter J. Common Arterial Trunk: Physiology, Imaging, and Management. Semin Cardiothorac Vasc Anesth. 2019 Jun;23(2):225-236. doi: 10.1177/1089253218821382. 
  76. Koplay M., Cimen D., Sivri M., et al. Truncus arteriosus: Diagnosis with dual-source computed tomography angiography and low radiation dose. World J Radiol. 2014;6(11):886-889. doi:10.4329/wjr.v6.i11.886
  77. Beerbaum P., Korperich H., Barth P. et al. Non-invasive quantification of left-to-right shunt in pediatric patients. Phasecontrast cine magnetic resonance imaging compared with invasive oximetry. Circulation 2001; 103: 2476–2482.
  78. Zabal C., García-Montes J.A., Buendía Hernández A., et al. Percutaneous closure of hypertensive ductus arteriosus. Heart. 2010;96:625–9.
  79. Yan C., Zhao S., Jiang S., et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007; 93:514–8.
  80. Sitbon O., Humbert M., Jaı¨s X., Ioos V., Hamid A.M., Provencher S., Garcia G., Parent F., Herve P., Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
  81. Barst R., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski A., Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S40–S47.
  82. Baumgartner H., De Backer J., Babu-Narayan S.V. et al. 2020 ESC Guidelines for themanagement of adult congenital heart disease. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC)//European Heart Journal (2020) 00, 1-83.
  83. Stapleton G.E., Wilmot I., Suh E.J. Cardiac catheterisation of patients with common arterial trunk and transposition of the great arteries. Cardiol Young. 2012 Dec;22(6):687-90. doi: 10.1017/S1047951112001515. 
  84. Mair D.D., Ritter D.G., Davis G.D., Wallace R.B., Danielson G.K., McGoon D.C. Selection of patients with truncus arteriosus for surgical correction; anatomic and hemodynamic considerations. Circulation. 1974 Jan;49(1):144-51. doi: 10.1161/01.cir.49.1.144. 
  85. Knuuti J., Wijns W., Saraste A., et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019 Aug 31. pii: ehz425.
  86. Горбачевский С.В. Легочная гипертензия при дефекте межжелудочковой перегородки. Кардиология, 1990, 30 (3):116-9.
  87. Inuzuka R., Diller G., Borgia F., et al. Comprehensive Use of Cardiopulmonary Exercise Testing Identifies Adults With Congenital Heart Disease at Increased Mortality Risk in the Medium Term. Circulation. 2012; 25: 250–259.
  88. Reddy V.M., Hanley F.L. Cardiac surgery in infants with very low birth weight. Semin Pediatr Surg. 2000 May;9(2):91-5. doi: 10.1016/s1055-8586(00)70023-0. 
  89. Saxena A., Relan J., Agarwal R., et al. Working group on Management of Congenital Heart Disease in India. Indian Guidelines for Indications and Timing of Intervention for Common Congenital Heart Diseases: Revised and Updated Consensus Statement of the Working Group on Management of Congenital Heart Diseases. Abridged Secondary Publication. Indian Pediatr. 2020 Feb 15;57(2):143-157. 
  90. Oppido G., Pace Napoleone C., Formigari R., Gabbieri D., Pacini D., Frascaroli G., Gargiulo G. Outcome of cardiac surgery in low birth weight and premature infants. Eur J Cardiothorac Surg. 2004 Jul;26(1):44-53. doi: 10.1016/j.ejcts.2004.04.004.
  91. Rao P.S. Management of Congenital Heart Disease: State of the Art-Part II-Cyanotic Heart Defects. Children (Basel). 2019;6(4):54. Published 2019 Apr 4. doi:10.3390/children6040054
  92. Шарыкин А.С. Врожденные пороки сердца. Второе издание. Бином. 2009
  93. Kaemmerer H., Apitz C., Brockmeier K., et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 272S:79-88.
  94. Broberg C.S., Ujita M., Prasad S., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50: 634–642.
  95. Dickstein K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–2442.
  96. Grünig, E., Benjamin, N., Krüger, U., et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.
  97. Buchhorn R., Hulpke-Wette M., Hilgers R., Bartmus D., Wessel A., Bürsch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol. 2001 Jul;79(2-3):167-73. doi: 10.1016/s0167-5273(01)00413-2.
  98. Jain S., Vaidyanathan B. Digoxin in management of heart failure in children: Should it be continued or relegated to the history books?. Ann Pediatr Cardiol. 2009;2(2):149-152. doi:10.4103/0974-2069.58317
  99. Jentzer, J.C., Mathier, M.A. Pulmonary Hypertension in the Intensive Care Unit. Journal of Intensive Care Medicine. 2015; 31(6): 369–385.
  100. Marino P.L. ред. А.И. Мартынов. Интенсивная терапия (перевод с англ.). ГЭОТАР Медицина. Москва. 1998
  101. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2:123-137.
  102. Galie` N, Ghofrani HA, Torbicki A, et al, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157.
  103. Евтушенко А.В. Оценка фармакологических параметров препарата мацитентан – нового антагониста рецепторов эндотелина для лечения легочной артериальной гипертензии. Кардиология 2015; 3: 81-83.
  104. Gatzoulis M.A., Beghetti M., Galie N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; Vol.127 (1): 27-32.
  105. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121:20–5.
  106. Baptista R., Castro G., da Silva A.M., et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013;32:123–9.
  107. Rubin L.J., Badesch D.B., Barst R.J., Galie` N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
  108. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galie` N., Boonstra A., Rubin L.J., Horn E.M., Manes A., Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353–359.
  109. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., Rubin L.J. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119–1123.
  110. Simonneau G., Torbicki A., Hoeper M.M., Delcroix M., Karlocai K., Galie` N., Degano B., Bonderman D., Kurzyna M., Efficace M., Giorgino R., Lang I.M. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874–880.
  111. Chen S.L., Zhang F.F., Xu J., Xie D.J., Zhou L., Nguyen T., Stone G.W. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62: 1092–1100
  112. Talwar S., Saxena R., Choudhary S.K. et al. Persistent truncus arteriosus repaired beyond infancy. Indian J Thorac Cardiovasc Surg 28, 171–176 (2012). https://doi.org/10.1007/s12055-012-0162-4
  113. Gatzoulis M.A. Landzberg M., BeghettiM.. et al. Evaluation of Macitentan in Patients with Eisenmenger Syndrome: Results from the Randomized, Controlled MAESTRO Study. Circulation 2019; Vol.139 (1): 51–63.
  114. Singh T.P., Rohit M., Grover A., et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1–851.e5.
  115. Pascall E., Tulloh R.M. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018;14(4):343-353. doi:10.2217/fca-2017-0065
  116. Mukhopadhyay S., Sharma M., Ramakrishnan S., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006; 114: 1807–1810.
  117. McLaughlin V., Channick R.N., Ghofrani H.A., Lemarie´ J.C., Naeije R., Packer M., Souza R., Tapson V.F., Tolson J., Al Hit Hi, Meyer G., Hoeper M.M. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46:405–413.
  118. Dardi F., Manes A., Palazzini M., Bachetti C., Mazzanti G., Rinaldi A., Albini A., Gotti E., Monti E., Bacchi Reggiani M.L., Galie` N. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015;46:414–421.
  119. Galie` N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31: 2080–2086.
  120. Sitbon O., Jaı¨s X., Savale L., Cottin V., Bergot E., Macari E.A., Bouvaist H., Dauphin C., Picard F., Bulifon S., Montani D., Humbert M., Simonneau G. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43:1691–1697.
  121. Galie` N., Barbera J.A., Frost A., Ghofrani A., Hoeper M., Mc Laughlin V.V., Peacock A., Simonneau G., Vachiery J.L., Grunig E., Oudiz R.G., Vonk-Nordegraaf A., White J., Blair C., Gillies H.C., Miller L., Harris J.H.N., Langley J., Rubin L.J. Initial Use of Ambrisentan plus Tadalafi in Pulmonary Arterial Hypertension. New Engl J Med 2015; 379(9):834–844.
  122. Juaneda E., Haworth S.G. Pulmonary vascular structure in patients dying after a Fontan procedure. The lung as a risk factor. Br Heart J. 1984 Nov;52(5):575-80. doi: 10.1136/hrt.52.5.575. 
  123. Naimo P.S., Fricke T.A., Yong M.S., d"Udekem Y., Kelly A., Radford D.J., Bullock A., Weintraub R.G., Brizard C.P., Konstantinov I.E. Outcomes of Truncus Arteriosus Repair in Children: 35 Years of Experience From a Single Institution. 2016 SummerSemin Thorac Cardiovasc Surg. 28(2):500-511.
  124. Sandrio S., Rüffer A., Purbojo A., Glöckler M., Dittrich S., Cesnjevar R. Common arterial trunk: current implementation of the primary and staged repair strategies. Interact Cardiovasc Thorac Surg. 2015 Dec;21(6):754-60.
  125. Davis J.T., Ehrlich R., Blakemore W.S., Lev M., Bharati S. Truncus arteriosus with interrupted aortic arch: report of a successful surgical repair. Ann Thorac Surg. 1985 Jan;39(1):82-5. doi: 10.1016/s0003-4975(10)62528-3. 
  126. Konstantinov I.E., Karamlou T., Blackstone E.H., Mosca R.S., Lofland G.K., Caldarone C.A., Williams W.G., Mackie A.S., McCrindle B.W. Truncus arteriosus associated with interrupted aortic arch in 50 neonates: a Congenital Heart Surgeons Society study. Ann Thorac Surg. 2006 Jan;81(1):214-22. doi: 10.1016/j.athoracsur.2005.06.072.
  127. Mohsin M., Ahmed W., Karim F., Akhtar Sadqani S. Hybrid procedure as a palliation approach in truncus arteriosus with interrupted aortic arch, Progress in Pediatric Cardiology, Volume 56, 2020, https://doi.org/10.1016/j.ppedcard.2019.101174.
  128. Sakata M., Hayabuchi Y., Inoue M., Kagami S. Stenting of ductus arteriosus in a neonate with truncus arteriosus and interrupted aortic arch associated with a right aortic arch. Pediatr Cardiol 2009;30(8):1180. Nov 1.
  129. Takabayashi S., Shimpo H., Yokoyama K., Kajimoto M. Truncus arteriosus repair after palliative bilateral pulmonary artery banding. Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):35-7. doi: 10.1007/s11748-006-0065-7. 
  130. Kobayashi T, Miyamoto T, Kobayashi T, Ikeda K, Koizuka K, Okamoto H, Miyaji K. Staged repair of truncus arteriosus with interrupted aortic arch: adjustable pulmonary artery banding. Ann Thorac Surg. 2010 Mar;89(3):973-5. doi: 10.1016/j.athoracsur.2009.07.044. 
  131. Silversides C.K., Marelli A,. Beauchesne L., et al. Canadian Cardiovascular Society 2009 consensus conference on the management of adults with congenital heart disease: executive summary. Can J Cardiol. 2010;26: 143–50.
  132. Neutze J.M., Ishikawa T., Clarkson P.M., Calder A.L., Barratt-Boyes B.G., Kerr A.R. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol. 1989 Feb 1;63(5):327-31. doi: 10.1016/0002-9149(89)90340-8.
  133. Weil J. Guidelines for the Management of Congenital Heart Diseases in Childhood and Adolescence. Cardiology in the Young. 2017: 27(Suppl. 3): S1–S105.
  134. Sitbon O, Humbert M, Jaı¨s X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
  135. Barst R, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski A, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S40–S47.
  136. Jonas R.A. Comprehensive Surgical Management of Congenital Heart Disease. 2nd Edition/ Taylor and Fracnis Group. 2014.
  137. Barbero-Marcial M., Riso A., Atik E., Jatene A. A technique for correction of truncus arteriosus types I and II without extracardiac conduits. J Thorac Cardiovasc Surg. 1990 Feb;99(2):364-9.
  138. Isomatsu Y., Shin"oka T., Aoki M., Terada M., Takeuchi T., Hoshino S., Takanashi Y., Imai Y., Kurosawa H. Establishing right ventricle-pulmonary artery continuity by autologous tissue: an alternative approach for prosthetic conduit repair. Ann Thorac Surg. 2004 Jul;78(1):173-80. doi: 10.1016/j.athoracsur.2003.11.045. 
  139. Kang Y., Kwak J.G., Min J., Lim J.H., Kim W.H. Twenty-Year Experience with Truncus Arteriosus Repair: Changes in Risk Factors in the Current Era. Pediatr Cardiol. 2021 Jan;42(1):123-130. doi: 10.1007/s00246-020-02461-5. 
  140. Seese L.M., Turbendian H.K., Castrillon C.E.D., Morell V.O. The Fate of Homograft Versus Polytetrafluoroethylene Conduits After Neonatal Truncus Arteriosus Repair. World J Pediatr Congenit Heart Surg. 2020 Mar;11(2):141-147. doi: 10.1177/2150135119888141. 
  141. Popelová J., Oechslin E., Kaemmerer H., Sutton M. Congenital Heart Disease in Adults 2008 Informa UK Ltd.- 183p. ISBN 13: 978 1 84184 584 5.
  142. Christie J.D., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult lung and heart-lung transplant report 2012. J. Heart Lung Transplant. 2012; 31:1073–1086.
  143. Fadel E., Mercier O., Mussot S., et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010; 38:277–284.
  144. Karamlou T., Hirsch J., Welke K., et al. A United Network for Organ Sharing analysis of heart transplantation in adults with congenital heart disease: outcomes and factors associated with mortality and retransplantation. J Thorac Cardiovasc Surg. 2010;140:161–8.
  145. Goerler H., Simon A., Gohrbandt B., et al. Heart-lung and lung transplantation in grown-up congenital heart disease: long-term single centre experience. Eur J Cardiothorac Surg. 2007;32:926–31.
  146. Burchill L.J., Edwards L.B., Dipchand A.I., et al. Impact of adult congenital heart disease on survival and mortality after heart transplantation. J Heart Lung Transplant. 2014;33:1157–63.
  147. Greutmann M., Prкtre R., Furrer L., et al. Heart transplantation in adolescent and adult patients with congenital heart disease: a casecontrol study. Transplant Proc. 2009;41:3821–6.
  148. McElhinney D.B., Hellenbrand W.E., Zahn E.M., et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US Melody valve trial. Circulation. 2010;122:507–16.
  149. Niemantsverdriet M.B.A., Ottenkamp J., Gauvreau K., et al. Determinants of right ventricular outflow tract conduit longevity: a multinational analysis. Congenit Heart Dis. 2008;3:176–84.
  150. Batra A.S., McElhinney D.B., Wang W., et al. Cardiopulmonary exercise function among patients undergoing transcatheter pulmonary valve implantation in the US Melody valve investigational trial. Am Heart J. 2012;163:280–7.
  151. Souza R.o, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  152. Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
  153. Peacock A., Murphy N.., McMurrey,J. et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104–109.
  154. Souza R.О, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  155. Coats L., Khambadkone S., Derrick G., et al. Physiological and clinical consequences of relief of right ventricular outflow tract obstruction late after repair of congenital heart defects. Circulation. 2006;113:2037–44.
  156. Feltes T.F., Bacha E., Beekman R.H. 3rd, et al. American Heart Association Congenital Cardiac Defects Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; American Heart Association. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011 Jun 7;123(22):2607-52. doi: 10.1161/CIR.0b013e31821b1f10.
  157. Алекян Б.Г. Рентгенэндоваскулярная хирургия. Национальное руководство в 4-х томах // Под ред. Алекяна Б.Г. Издательство «Литтерра». 2017.
  158. Базылев В.В., Воеводин А.Б., Черногривов А.Е., Сластин Я.М. Трансвентрикулярная имплантация протеза "МедЛАБ-КТ" в позицию клапана легочной артерии. Грудная и сердечно-сосудистая хирургия. 2019. Т.61 №6. С. 546-549. DOI: 10.24022/0236-2791-2019-61-6-546-549
  159. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., др. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых у новорожденных и детей. Методические рекомендации. М.: НЦССХ им.А.Н. Бакулева РАМН; 2014.
  160. Рыбка М.М., Хинчагов Д.Я. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения кардиохирургических операций, выполняемых при ишемической болезни сердца, патологии клапанного аппарата, нарушениях ритма, гипертрофической кардиомиопатии, аневризмах восходящего отдела аорты у пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им.А.Н. Бакулева РАМН; 2015
  161. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Никулкина Е.С. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им.А.Н. Бакулева РАМН; 2018.
  162. Brugada J., Blom N., Sarquella-Brugada G. et al. Рharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Europace. 2013 Sep; 15 (9):1337-82.
  163. Ревишвили А.Ш., Бойцов С.А., Покушалов Е.А., др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА), 2017 год.
  164. Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). ESC Scientific Document Group. Eur Heart J. 2015 Nov 1; 36 (41): 2793-2867.
  165. Oechslin E.N., Harrison D.A., Connelly M.S., et al. Mode of death in adults with congenital heart disease. Am J Cardiol2000;86:1111–1116.
  166. Rhodes C.J., Wharton J., Howard L., et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011; 38(6):1453–1460.
  167. Barst R., Ivy D., Widlitz A. C. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension // Clin Pharmacol Ther. 2003, 73: 372–382.
  168. Rosenzweig E. B., Ivy D. D., Widlitz A. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension // J Am Coll Cardiol. 2005, 46: 697–704.
  169. Hislop A., Moledina S., Foster H et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011;38(1):70-77.
  170. Barst R., Ivy D., Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372-382.
  171. Beghetti M., Haworth S., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948-955.
  172. Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
  173. Peacock A., Murphy N.., McMurrey,J. et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104–109.
  174. Souza R.О, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  175. Kimura-Hayama E. T. et al. Uncommon congenital and acquired aortic diseases: role of multidetector CT angiography //Radiographics. – 2010. – Т. 30. – №. 1. – С. 79-98.
  176. Ivy D., Rosenzweig E., Lemarie J. et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010;106(9):1332-1338.
  177. Souza R.o, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  178. Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
  179. Peacock A., Murphy N.., McMurrey,J. et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007;30:104–109.
  180. Souza R.О, Pulido T., Channick R.. et al. Long-Term Survival and Safety with Macitentan in Patients with Pulmonary Arterial Hypertension: Results from the SERAPHIN Study and Its Open-Label Extension. Pharmacological treatment of pulmonary hypertension 2017; May 1: A2294-A2294
  181. Klinger J. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28(1):143–167
  182. Сакалаускене Г., Цивинскене Г., Антушевас А., Цивинскас П. Фармакологические свойства петлевых диуретиков и их клинические эффекты. Кардиология. 2018;58(1):72–83.
  183. Курлыкина Н. В., Середенина Е. М., Орлова Я. А. Современные аспекты применения петлевых диуретиков при сердечной недостаточности. Терапевтический архив. 2017;89(9):115-119. https://doi.org/10.17116/terarkh2017899115-119.
  184. Бизунок, Н. А. Б59 Мочегонные средства : учеб.-метод. пособие / Н. А. Бизунок, А. В. Гайдук. – Минск : БГМУ, 2016. – 36 с. ISBN 978-985-567-557-1.
  185. Andrews LM, Puiman PJ, van der Sijs H, van Beynum IM. Een zuigeling met een digoxine-intoxicatie [A baby with digoxin toxicity]. Ned Tijdschr Geneeskd. 2015;159:A8706. Dutch. PMID: 25944069.
  186. Poole-Wilson PA, Robinson K. Digoxin--a redundant drug in congestive cardiac failure. Cardiovasc Drugs Ther. 1989 Jan;2(6):733-41. doi: 10.1007/BF00133201. PMID: 2488085.
  187. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart. 2007 Mar;93(3):350-4. doi: 10.1136/hrt.2006.100388.
  188. Carter NJ, Keating GM. Bosentan: in pediatric patients with pulmonary arterial hypertension. Paediatr Drugs. 2010;12(1):63-73. doi: 10.2165/11203970-000000000-00000. 
  189. Masarone D. et al. Pediatric heart failure: a practical guide to diagnosis and management //Pediatrics & Neonatology. – 2017. – Т. 58. – №. 4. – С. 303-312.
  190. Galie N., Beghetti M., Gatzoulis M. et al. Bosentan Therapy in Patients with Eisenmenger Syndrome. A multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006. 114; 48 – 54. https.://doi.org/10.1161/CIRCULATIONAHA. 106.630715 
  191. Keating GM. Macitentan: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2016 Dec;16(6):453-460. doi: 10.1007/s40256-016-0188-x. 
  192. Belge C, Delcroix M. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466618823440. doi: 10.1177/1753466618823440.
  193. Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ. 2021;11(1):2045894020979503. Published 2021 Jan 20. doi:10.1177/2045894020979503
  194. Moreno-Galdó A, Torrent-Vernetta A, de Mir Messa I, Rovira Amigo S, Gran Piña F, Gartner S, Albert Brotons D. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol. 2015 Apr;50(4):370-9. doi: 10.1002/ppul.23044.
  195. Simonca L, Tulloh R. Sildenafil in Infants and Children. Children (Basel). 2017;4(7):60. Published 2017 Jul 24. doi:10.3390/children4070060
  196. Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med. 2015;61(3):181-192. doi:10.4103/0022-3859.159421
  197. https://clinicaltrials.gov/ct2/show/NCT02562235#moreinfo. Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PATENT-CHILD)
  198. Spreemann T, Bertram H, Happel CM, Kozlik-Feldmann R, Hansmann G. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Pulm Circ. 2018;8(1):2045893217743123. doi:10.1177/2045893217743123
  199. Hansmann G, Meinel K, Bukova M, Chouvarine P, Wåhlander H, Koestenberger M; European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. J Heart Lung Transplant. 2020 Jul;39(7):695-706. doi: 10.1016/j.healun.2020.03.029. 
  200. Diller G. P. et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency //International journal of cardiology. – 2013. – Т. 167. – №. 3. – С. 840-847.
  201. Hascoet S. et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study //Archives of cardiovascular diseases. – 2017. – Т. 110. – №. 5. – С. 303-316.
  202. Kotlyar E. et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease //Cardiology in the Young. – 2006. – Т. 16. – №. 3. – С. 268-274.
  203. Chau E. M. C., Fan K. Y. Y., Chow W. H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension //International journal of cardiology. – 2007. – Т. 120. – №. 3. – С. 301-305.
  204. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации. 2020. Министерство Здравоохранения Российской Федерации. https://cr.minzdrav.gov.ru/recomend/159_1
  205. НохринА.В., КокоринС.Г., КидунТ.А., др. Диагностические критерии наиболее часто встречающихся врожденных пороков сердца и сосудов: тактика ведения и показания к хирургическому лечению. Мать и дитя в Кузбассе. 2007. № 2. С. 19-28.
  206. BolRaap G, Meijboom FJ, Kappetein AP, et al. Long-term follow-up and quality of life after closure of ventricular septal defect in adults. Eur J Cardiothorac Surg. 2007 32(2):215-9.
  207. Подзолков В.П., Кассирский Г.И. (ред.). Реабилитация больных после хирургического лечения врожденных пороков сердца. М.: НЦССХ им. А.Н. Бакулева; 2015.
  208. Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 1991; 68: 1491–7.
  209. Brauner R, Birk E, Sahar L, Vidbe BA. Surgical management ofventricular septal defect with aortic valve prolapse: Clinical considerations and results. Eur J CardiothoracSurg 1995; 9: 315–19.
  210. Otterstad JE, Nitter-Hague S, Myrhe E. Isolated ventricular septal defect in adults. Clinical and haemodynamic findings. Brit Heart J 1983; 50: 343–8.
  211. Perloff JK. The Clinical Recognition of Congenital Heart Disease, 4th edn. Philadelphia, PA: WB Saunders Company, 1994.
  212. Falk V. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease//European Journal of Cardio-Thoracic Surgery 52 (2017) 616–664.
  213. Kidd L, Driscoll DJ, Gersony WM et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1999; 87(Suppl I): I-38–I-51.
  214. Бойцов С.А. Смоленский А.В., Земцовский Э.В., др. Рекомендации по допуску спортсменов с отклонениями со стороны сердечно-сосудистой системы к тренировочно-соревновательному процессу. Конференция «СПОРТМЕД-2011». 2011, 8 декабря, Экспоцентр, Москва.
  215. Gabriel HM, Heger M, Innerhofer P, et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol2002;39:1066–1071.
  216. Stout K., Daniels C., Aboulhosn J. et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139 (14): e698-e800.
  217. Jochen Weil. Guidelines for the Management of Congenital Heart Diseases in Childhood and Adolescence. Cardiology in the Young. 2017: 27(Suppl. 3): S1–S105.
  218. Baumgartner H.,  De Backer J., Babu-Narayan S.V. et al. 2020 ESC Guidelines for themanagement of adult congenital heart disease. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC)//Eur Heart J, Volume 42, Issue 6, 2021, Pages 563–645, https://doi.org/10.1093/eurheartj/ehaa554
  219. Giglia T., Massicotte M., Tweddell J. et al. Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation.2013;128:2622-2703.
  220. Карахалис Н.Б., Ефимочкин Г.А., Шадрин А.К., Синьков С.В. Антитромботическая терапия у детей. Анестезиология и реаниматология.2018; 63(1): 46-55. DOI: http://dx.doi.org/10.18821/0201-7563-2018-63-1-46-55
  221. Myung K. Park. Pediatric Cardiology for Practitioners. Mosby; 6 edition, 2014.-688 p.
  222. Habib G., Lancellotti P., Antunes M.J. et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J Volume 36, Issue 44, 21 November 2015, Pages 3075–3128.
  223. Steppan J., Diaz-rodriguez N., Barodka V. M., et al. Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. Cureus 2018 10(1): e2072.
  224. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165–3241.
  225. Sliwa K, van Hagen IM, Budts W, et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016; 18 (9): 1119–28.
  226. Buber J, Assenza GE, Huang A, Valente AM, Emani SM, Gauvreau K, Marshal AC, McElhinney DB, Landzberg MJ. Durability of large diameter right ventricular outflow tract conduits in adults with congenital heart disease. Int J Cardiol. 2014 Aug 20;175(3):455-63. doi: 10.1016/j.ijcard.2014.06.023.
  227. Mohammadi, Siamak & Belli, Emre & Martinovic, Ivo & Houyel, Lucile & Capderou, André & Petit, Jérome & Planché, Claude & Serraf, Alain. (2005). Surgery for right ventricle to pulmonary artery conduit obstruction: Risk factors for further reoperation. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 28. 217-22. 10.1016/j.ejcts.2005.04.014. 

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу